Develops reagents for life sciences researchers to understand diseases and develop treatments.
Jul 2026Revenue $2.91B/yrExpenses $2.55B/yr
No trend
Figures by year
Is Revvity profitable?
Yes. In the 12 months to Jul 2026, revenue was $2.91B and expenses $2.55B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.86B | $2.50B | $357M |
| Dec 2024 | $2.76B | $2.41B | $347M |
| Dec 2023 | $2.75B | $2.45B | $301M |
| Jan 2023 | $3.31B | $2.57B | $743M |
| Jan 2022 | $3.83B | $2.57B | $1.26B |
| Jan 2021 | $2.66B | $1.80B | $867M |
| Dec 2019 | $2.88B | $2.52B | $362M |
| Dec 2018 | $2.78B | $2.45B | $324M |
| Dec 2017 | $2.26B | $1.96B | $296M |
| Jan 2017 | $2.12B | $1.82B | $295M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.